Analytical Data
-
Gene name
MHCA
- Application
-
Alternative Names
MHCA；Myosin-2 heavy chain
-
Species
E.coli
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P12844
-
Expression Region
全长
-
AA Sequence
full
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The research on MHCA (Major Histocompatibility Complex Class A) recombinant proteins has gained significant attention in the fields of immunology and vaccine development. MHCA molecules play a crucial role in the immune system by presenting peptide fragments derived from pathogens to T cells, thereby initiating an immune response. Understanding the structure and function of MHCA proteins is essential for developing targeted therapeutic strategies, including vaccines for infectious diseases and cancer. Recombinant technology allows for the production of these proteins in a controlled environment, enabling researchers to manipulate their structure for enhanced stability and immunogenicity. Furthermore, studies have shown that engineered MHCA proteins can improve antigen presentation efficiency, making them valuable tools for enhancing the efficacy of T cell-based therapies. The exploration of MHCA recombinant proteins is also vital for the development of diagnostics that can identify immune responses to specific antigens, facilitating personalized medicine approaches. As research progresses, these proteins hold the potential to advance our understanding of immune mechanisms and improve the effectiveness of immunotherapeutic interventions.
